CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....